CBL W802*

CI-VAR-00004713Explore in graph →CIViC 2703

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
CBL W802*	SU11274	Predictive	D	Supports Sensitivity Response	2	submitted	EID7298 In this preclinical study, overexpression of CBL mutations S80N/H94Y, Q249E, V391I, and W802* in A549 cell line as well as sh-RNA knockdown of CBL (sh-CBL) in H358 cells increased MET but not EGFR exp… (full text at CIViC) PMID 28835699 · Tan et al., 2017 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.